Unknown PHASE3 INTERVENTIONAL 2-arm NCT04326374

Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency

The Efficacy, Safety and Tolerability of TransCon hGH Administered Weekly Versus Daily hGH in Prepubertal Children With Growth Hormone Deficiency: a Randomized, Open-lable, Active-controlled, Parallel-group Study in China

Sponsor: Ascendis Pharma A/S

Conditions Endocrine System Diseases Growth Hormone Deficiency Hormones Pituitary Disease, Anterior Pituitary Diseases

Interventions TransCon hGH daily hGH

Updated 5 times since 2020 Last updated: Mar 27, 2020 Started: Dec 30, 2019 Primary completion: Apr 30, 2022 Completion: Apr 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04326374, this PHASE3 trial focuses on Endocrine System Diseases and Growth Hormone Deficiency and remains ongoing. Sponsored by Ascendis Pharma A/S, it has been updated 5 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
May 2022 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jan 2021 — May 2022 [monthly]

Recruiting PHASE3
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE3

First recorded

Dec 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ascendis Pharma A/S
Visen Pharmaceuticals (Shanghai) Co., Ltd.

Data source: Visen Pharmaceuticals (Shanghai) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China